busulfan and Glioma
busulfan has been researched along with Glioma in 8 studies
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 9.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "The glutathione synthase inhibitor, buthionine sulfoximine (BSO), specifically enhances the cytotoxic effects of treosulfan in human glioma cells." | 7.71 | CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. ( Baumgart, J; Seyfried, J; Stock, J; Weller, M; Wick, W; Wüllner, U, 2002) |
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 5.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "The glutathione synthase inhibitor, buthionine sulfoximine (BSO), specifically enhances the cytotoxic effects of treosulfan in human glioma cells." | 3.71 | CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. ( Baumgart, J; Seyfried, J; Stock, J; Weller, M; Wick, W; Wüllner, U, 2002) |
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Younis, IR | 1 |
| Elliott, M | 1 |
| Peer, CJ | 1 |
| Cooper, AJ | 1 |
| Pinto, JT | 1 |
| Konat, GW | 1 |
| Kraszpulski, M | 1 |
| Petros, WP | 2 |
| Callery, PS | 1 |
| ONESTI, P | 1 |
| WOODLIFF, HJ | 1 |
| Gururangan, S | 1 |
| Poussaint, TY | 1 |
| Hancock, ML | 1 |
| Phillips, PC | 1 |
| Friedman, HS | 2 |
| Bomgaars, L | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Reber, U | 1 |
| Wüllner, U | 2 |
| Trepel, M | 1 |
| Baumgart, J | 2 |
| Seyfried, J | 2 |
| Klockgether, T | 1 |
| Dichgans, J | 1 |
| Weller, M | 2 |
| Coggins, CA | 1 |
| Elion, GB | 1 |
| Houghton, PJ | 1 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Colvin, OM | 1 |
| Bigner, DD | 1 |
| Bouffet, E | 1 |
| Raquin, M | 1 |
| Doz, F | 1 |
| Gentet, JC | 1 |
| Rodary, C | 1 |
| Demeocq, F | 1 |
| Chastagner, P | 1 |
| Lutz, P | 1 |
| Hartmann, O | 1 |
| Kalifa, C | 1 |
| Wick, W | 1 |
| Stock, J | 1 |
| Mungyerová, G | 1 |
| Jacz, K | 1 |
| Kuzma, I | 1 |
| Babusiková, O | 1 |
| Kalafut, F | 1 |
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis[NCT00006246] | Phase 1 | 28 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors[NCT02684071] | Phase 2 | 3 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Lack of additional funding; patients (3) no longer receiving intervention.) | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
2 trials available for busulfan and Glioma
| Article | Year |
|---|---|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Experiences with malignant brain tumours in clinic and in tissue culture.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Arsenicals; Astrocytoma; Brain Neoplasms; Busulfan; Clin | 1965 |
Other Studies
6 other studies available for busulfan and Glioma
| Article | Year |
|---|---|
Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.
Topics: Alanine; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cell Line, Tumor; Glioma; Glutathione | 2008 |
EFFECT OF DRUGS ON CELLS IN VITRO.
Topics: Animals; Busulfan; Glioma; In Vitro Techniques; Leukemia; Leukemia, Experimental; Leukemia, Myeloid; | 1963 |
Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Buthionine Sulfoximine; Drug Synergism | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biops | 2000 |
CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Blood Cell C | 2002 |